The American College of Cardiology/American Heart Association (ACC/AHA) task force on clinical practice guidelines has updated its 2013 cholesterol guideline. The 2018 guideline narrows the use of the atherosclerotic cardiovascular disease (ASCVD) risk calculator, provides more guidance on the use of risk-enhancing factors in making statin therapy decisions and recommends therapy options for achieving low-density lipoprotein cholesterol (LDL-C) targets. The updated guidelines have appeared in the Journal of the American College of Cardiology.
- A nonfasting plasma lipid profile can be obtained to estimate ASCVD risk and document baseline LDL-C in adults 20 years and older who are not on lipid-lowering therapy.
- Maximally tolerated statin therapy is recommended for patients 20 to 75 years of age with an LDL-C level of 190 mg per dL or greater.
- Moderate-intensity statin therapy should be initiated without calculating a 10-year ASCVD risk for patients 40 to 75 years of age with diabetes mellitus.
- Patients without diabetes at intermediate risk of ASCVD with LDL-C levels of 70 to 189 mg per dL should be treated with a moderate-intensity statin for a goal of 30% or greater reduction in LDL-C levels.
- Individuals with LDL-C ≥ 190 mg/dL or triglycerides ≥ 500 mg/dL should be evaluated for secondary causes of hyperlipidemia.
- A heart-healthy lifestyle should be emphasized for all individuals. Lifestyle therapy should be the primary intervention for metabolic syndrome.
- Adults ≥ 21 years of age with a primary LDL-C ≥ 190 mg/dL should be treated with high-intensity statin therapy unless contraindicated.
- Adults 40-75 years of age with an LDL-C 70-189 mg/dL without clinical ASCVD or diabetes and an estimated ten-year ASCVD risk ≥ 7.5% should be treated with moderate- to high-intensity statin therapy.
- Adults 40-75 years of age with an LDL-C 70-189 mg/dL without clinical ASCVD or diabetes and an estimated ten-year ASCVD risk 5- 7.4% may consider moderate intensity statin therapy if there are additional risk factors. The decision to treat should include a discussion of the benefits and risks between the patient and clinician.
- Adults 40-75 years of age with diabetes mellitus and an LDL-C 70-189 mg/dL should be treated with moderate-intensity statin therapy.
- Individuals ≤ 75 years of age who have clinical ASCVD should be treated with high-intensity statin therapy unless contraindicated.
- In adults with very high-risk ASCVD, addition of a nonstatin may be considered at a LDL-C threshold of 70 mg/dL (1.8 mmol/L). Very high-risk includes a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions.
................................ Advertisement ................................
................................ Advertisement ................................
Based on high-quality evidence from randomized controlled trials (RCTs), high-intensity statin therapy should be instituted with a goal of lowering LDL-C levels by 50% or more in patients with ASCVD up to 75 years of age. If treatment is not tolerated, then moderate-intensity therapy should be used with a goal of achieving a 30% to 49% reduction in LDL-C levels. Based on nonrandomized trials, patients at very high risk (history of multiple ASCVD events or one event with multiple high-risk comorbidities) should be considered for treatment with maximally tolerated statin doses and ezetimibe (Zetia) before considering the addition of a proprotein convertase subtilisin/kexin type 9 inhibitor
Based on moderate-quality evidence from RCTs, maximally tolerated statin therapy is recommended for patients 20 to 75 years of age with an LDL-C level of 190 mg per dL (4.92 mmol per L) or greater.
Based on high-quality evidence from RCTs, moderate-intensity statin therapy should be initiated without calculating a 10-year ASCVD risk for all patients 40 to 75 years of age with diabetes mellitus.
Moderate-quality evidence from nonrandomized studies recommends estimating the 10-year ASCVD risk of a first fatal or nonfatal myocardial infarction or stroke by using the race and sex-specific pooled cohort equations. Patients should then be categorized as low (less than 5%), borderline (5% to 7.4%), intermediate (7.5% to 19.9%), or high (20% or greater) risk. High-quality evidence from RCTs recommends that patients 40 to 75 years of age without diabetes who are at intermediate risk with LDL-C levels of 70 to 189 mg per dL (1.81 to 4.90 mmol per L) should be treated with a moderate-intensity statin. A 30% or greater reduction in LDL-C levels is recommended, and in high-risk patients a 50% or greater reduction is recommended.
The physician and patient should discuss risk factors before starting statin therapy. The conversation should include major risk factors such as cigarette smoking, elevated blood pressure, LDL-C levels, A1C (if indicated), and calculated 10-year risk of ASCVD; the presence of risk-enhancing factors; the potential benefits of lifestyle and statin therapies; the potential for adverse effects and drug−drug interactions; cost of therapy; and patient preferences and values in shared decision-making.
Risk-enhancing factors include a family history of premature ASCVD; persistently elevated LDL-C levels of 160 mg per dL (4.14 mmol per L) or greater; metabolic syndrome; chronic kidney disease; history of preeclampsia or premature menopause (younger than 40 years); chronic inflammatory disorders (e.g., rheumatoid arthritis, psoriasis, chronic HIV infection); high-risk ethnic groups (e.g., south Asian descent); persistent triglyceride levels of 175 mg per dL (2.0 mmol per L) or greater; and, if measured in selected individuals, an apolipoprotein B level of 130 mg per dL (1.3 g per L) or greater, high-sensitivity C-reactive protein level of 2.0 mg per L (19.05 nmol per L) or greater, an ankle-brachial index less than 0.9, and lipoprotein (a) level of 50 mg per dL (1.79 μmol per L) or greater, especially at higher values of lipoprotein (a).
Monitoring Response to Therapy
Based on high-quality RCTs, fasting lipid measurement should be repeated four to 12 weeks after starting the statin or making a dose adjustment to assess adherence and response to LDL-C−lowering medications and lifestyle changes. Following that, lipid measurement should be repeated every three to 12 months as needed.
- Addition of nonstatin drug therapy should be considered at a threshold LDL-C level of at least 70 mg per dL on maximal statin therapy in patients with ASCVD at very high risk.
- it may be beneficial to treat patients 20 to 75 years of age who have an LDL-C level of 190 mg per dL or greater with ezetimibe if they have not been able to achieve a 50% reduction in LDL-C level while receiving maximally tolerated statin therapy and/or still have an LDL-C level of at least 100 mg per dL (2.59 mmol per L).
- The 10-year risk of a first ASCVD event can be assessed in patients 40 to 75 years of age with diabetes and an LDL-C level of 70 to 189 mg per dL.
- Patients with diabetes who have multiple ASCVD risk factors should be treated with high-intensity statin therapy with a goal of reducing LDL-C levels by 50% or more.
- Patients 40 to 75 years without diabetes who have a 10-year risk of 7.5% to 19.9% and risk-enhancing factors should start or intensify statin therapy.
- Patients should be advised to obtain a coronary artery calcium (CAC) score for patients 40 to 75 years of age with an LDL-C level of 70 to 189 mg per dL and a 10-year ASCVD risk of 7.5% to 19.9% if a decision about statin therapy is uncertain.
- If the CAC score is zero, statin therapy should be withheld or delayed unless the patient is a cigarette smoker, has diabetes, or has a strong family history of premature ASCVD. A CAC score of 1 to 99 suggests statin therapy, particularly for patients 55 years and older. If the CAC score is 100 or greater or in the 75th percentile or greater, statin therapy is indicated for any patient unless otherwise deferred by the outcome of the physician-patient risk discussion.
For further reference log on to
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as an Editor-in-Chief for the Speciality Medical Dialogues section. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc.
Before Joining Medical Dialogues, he has served at important positions in the medical industry in India including as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils in India. Email: firstname.lastname@example.org. Contact no. 011-43720751
To know about our editorial team click here